REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

Data Readoutpositivesurabgene lomparvovecPositive

AI Analysis

Summary

REGENXBIO presented positive three-year durability data for surabgene lomparvovec gene therapy in diabetic retinopathy, showing sustained efficacy with majority of patients achieving >2-step DRSS improvement and no vision-threatening events or need for additional treatment.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Three-year durability data showing majority of Dose Level 3 participants with NPDR demonstrated >2-step DRSS improvement at 3 years post-treatment, with no vision-threatening events and no additional treatment needed for diabetic retinopathy

Importance:7/10

Sentiment:

0.85

gene therapydiabetic retinopathydurability dataophthalmologyDRSS improvement

Related Companies

$RGNX

Read the original article

Published by PR Newswire Biotech on September 24, 2026 11:17 PM

Read Original